Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Dapagliflozin Monotherapy in Treatment-Naive Type 2 Diabetes
NCT00263276Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2005
- Primary completion
- Feb 2007
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of dapagliflozin in type 2 diabetes mellitus (T2DM), sponsored by AstraZeneca. Started Dec 2005; status: completed.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00263276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00263276.